Published in Cancer Weekly, May 5th, 2009
Abbott will gain access to HUYA's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly